Management of localized myxoid liposarcoma has traditionally required a standard preoperative radiation dose of 50 Gy. However, the long-term results of the DOREMY trial suggest a new standard of care. Specifically, myxoid liposarcoma radiotherapy dose reduction to 36 Gy achieves exceptional local control while significantly minimizing treatment-related morbidity.

Efficacy of Reduced-Dose Myxoid Liposarcoma Radiotherapy

The DOREMY trial enrolled 90 patients across nine tertiary sarcoma centers. Each patient received 36 Gy in once-daily 2-Gy fractions before surgical resection. Furthermore, the 5-year follow-up data revealed a local recurrence-free survival rate of 97.4%. Consequently, this lower dose does not appear to compromise oncological safety. Additionally, the overall survival rate at five years was 88.5%, reinforcing the long-term viability of this de-escalated regimen.

Morbidity and Late Toxic Effects

Minimizing side effects is a primary goal of dose reduction. In this study, 21% of patients experienced wound complications. Only 16% of these individuals required further surgical intervention. Moreover, late toxic effects remained remarkably low. Only 3% of participants reported grade 3 late toxicity. These findings suggest that 36 Gy is a safer alternative to the conventional 50 Gy dose. Therefore, patients experience fewer permanent complications like fibrosis or joint stiffness.

Clinical Implementation and Shared Decision-Making

Myxoid liposarcoma is uniquely radiosensitive compared to other soft tissue sarcomas. This biological characteristic allows for effective tumor volume reduction at lower doses. Given that phase 3 trials are impractical for such rare cancers, these phase 2 findings provide high-level evidence. Clinicians should discuss this 36 Gy approach with patients to optimize long-term quality of life. This strategy balances effective tumor management with a superior safety profile.

Frequently Asked Questions

How does the DOREMY protocol differ from standard radiotherapy?

The DOREMY protocol uses a reduced total dose of 36 Gy delivered in 18 fractions. This is significantly lower than the standard 50 Gy dose delivered in 25 fractions for other soft tissue sarcomas.

Is this dose reduction safe for all liposarcomas?

No, this reduction specifically applies to translocation-confirmed myxoid liposarcoma. This subtype is exceptionally sensitive to radiation, unlike other varieties like pleomorphic liposarcoma.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

Lansu J et al. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: The Phase 2 DOREMY Nonrandomized Clinical Trial. JAMA Oncol. 2026 May 16. doi: 10.1001/jamaoncol.2026.1577. PMID: 42141895.

Lansu J, et al. Preoperative radiotherapy dose reduction in patients with myxoid liposarcoma: Results of the DOREMY trial. JAMA Oncol. 2020;6(12):e205864.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2024.